BACTERIOPHAGE HAVING MULTIPLE HOST RANGE

Abstract: The present invention discloses compositions and methods for the prophylaxis and treatment of bacterial infections by the use of polyvalent bacteriophage having multiple host range.

Description: Bacteriophage Having Multiple Host Range Field of the Invention The present invention discloses compositions and methods for the prophylaxis and treatment of bacterial infections by the use of polyvalent bacteriophage having multiple host range. Background of the Invention Escherichia coli capsular polysaccharides (K antigens) have often been associated with increased virulence (17). The Kl antigen in particular increases the invasiveness of E. coli, and these strains are often involved in cases of meningitis and septicemia (32). These polysaccharide coats also act as recognition sites for bacteriophages, which often carry tail spikes that contain polysaccharide depolymerization activities. Several Kl specific phages have been described (10), one of which, ΦK1Ε, was found to possess N-acetylneuraminidase (endosialidase) as a part of the tail fiber protein (37). This enzyme catalyzes the cleavage of -2,8-linked poly- N-acetylneuraminic acid carbohydrate polymer of the Kl capsule. It has been suggested that the tail fiber protein is involved in both adsorption to the cell surface and penetration into the cell by enzymatically degrading the polysaccharide capsule. The ΦK1Ε endosialidase gene has been cloned and sequenced (20). A similar gene has been cloned and sequenced from ΦK1F (29). ΦK5 is a related bacteriophage specific for E. coli strains that display the K5 antigen, a polymer consisting of a repeating structure of 4-linked a-N-acetylglucosamine and β-glucuronic acid (N-acetyl heparosin). In this case, ΦK5 encodes a tail associated K5 specific lyase protein that is also responsible for attachment to the cell surface and degradation of the K5 polysaccharide capsule (12,14). Phage have also been found that are specific for other E. coli polysaccharide antigens including K3, K7, K12, K13, and K20 (26,27); all probably possess specific polysaccharide depolymerization activities as part of the phage particle. Both ΦK5 and ΦK1E have a Salmonella phage SP6-like promoter upstream of their tail proteins as well as a region of sequence similarity, which is just downstream of the lyase gene of ΦK5 and just upstream of the endosialidase gene of ΦK1E (6). The sequences upstream of the tail gene promoters in ΦK1E, and ΦK5 are highly similar as well. ΦK5, ΦK1E and SP6 share a common morphology and life cycle, suggesting that they may be closely related. Antibiotics superseded the potential use of bacteriophage in the treatment of infections. The extensive use of antibiotics has led to antibiotic- resistant bacterial pathogens. Thus, investigators have reassessed bacteriophage therapy and prophylaxis. However, one major obstacle that is frequently raised to the use of bacteriophage is that of their excessively narrow host range. There is a need for bacteriophage having multiple host range for use in therapy and prophylaxis. Summary of the Invention A virulent double stranded DNA bacteriophage, ΦK1-5 has been isolated and was found to be capable of infecting E. coli strains that possess either the Kl or the K5 polysaccharide capsule. Electron micrographs show that the virion consists of a small icosohedral head with short tail spikes, similar to members of the Podoviridae family. DNA sequence analysis of the region encoding the tail fiber protein showed two open reading frames encoding previously characterized hydrolytic phage tail fiber proteins. The first is the K5 lyase protein gene of ΦK5, which allows this phage to specifically infect K5 E. coli strains. A second open reading frame encodes a protein almost identical in amino acid sequence to the N-acetylneuraminidase (endosialidase) protein of ΦK1E, which allows this phage to specifically infect Kl strains of E. coli. We provide experimental evidence that mature phage particles contain both tail fiber proteins, and mutational analysis indicates that each protein can be independently inactivated. A comparison of the tail gene regions of ΦK5, ΦK1E, and ΦK1-5 shows that the genes are arranged in a modular or cassette configuration. The demonstration that a phage can contain multiple tail proteins that expand its host range is useful in generating phage with broad-spectrum antibacterial properties for therapy and prophylaxis of bacterial infections. Brief Description of the Drawings Figure 1. Electron micrograph of ΦK1-5 negatively stained with phosphotungstic acid at a magnification of XI 15,500. Morphologically this phage and can be classified in the Podoviridae family which includes T7 and SP6. Figure 2. Comparison of the coding regions of the tail proteins of ΦK1-5, ΦK5, and ΦKIE. All three phages share sequence similarity in the upstream region (which contains an SP6 promoter) as well as an 85-base intergenic region. Just downstream of the promoter, ΦK1-5 and ΦK5 encode a lyase protein and ΦKIE encodes ORF L . Immediately following the termination codons of the lyases or ORF L is the intergenic region that contains a potential hairpin structure, the first of which could be a Rho-independent transcription terminator. Immediately following this, ΦK1-5 and ΦKIE encode an endosialidase where ΦK5 encodes ORF P . None of the three phages have any coding regions downstream, and the DNA molecule ends in all three cases. No sequence similarity exists in this terminal region. Figure 3. Two possible models for the arrangement of the tail proteins on the phage capsid. (a) There are three copies of each tail forming a hexamer. (b) There are six copies of each tail. One is attached to the head and is part of the "core" of the tail. The other is then attached to the first tail protein, in effect making a longer tail fiber with two different enzymatic activities. Figure 4. Comparison of the coding regions of the tail proteins of ΦK1-5, ΦK5, ΦKIE, and SP6. Brief Description of the Sequences SEQ ID NO:l is the DNA sequence of the tail gene region of ΦK1-5. SEQ ID NO:2 is the DNA sequence of ΦSP6 tail gene. SEQ ID NO:3 is the DNA sense sequence of ΦK1-5. SEQ ID NO:4 is the DNA antisense sequence of ΦK1-5. Brief Description of the Biological Deposits ΦK1-5 was deposited as ATCC Accession No. PTA-3495 on July 2, 2001 with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, USA. This deposit was made under the provisions of the Budapest Treaty on the international Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from date of deposit. The deposit will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Applicant and ATCC which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14). Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws. Detailed Description of the Preferred Embodiment We have discovered that it is possible to express more than one host specific tail protein in a single bacterial viral strain and that expression of these tail proteins permits the virus to infect multiple specific hosts. This discovery facilitates the genetic engineering of phage with expanded host ranges. For example, there are phage that can infect E. coli strains that contain the Kl polysaccharide in their outer capsule. Such E. coli bacterial strains are often involved in meningitis and septicemia, as Kl polysaccharide increases the invasiveness of the bacteria (32). A phage (ΦKIE) possesses a tail protein with endosialdase activity that can infect strains of E. coli containing the Kl polysaccharide. This endosialdase allows the phage ΦKIE to specifically attach and degrade the Kl polysaccharide (37). Similarly, phage ΦK5 can infect K5 strains of E. coli. The K5 strains of E. coli are commonly a cause of urinary tract infections (11). The phage ΦK5 contains a tail protein that has lyase activity that allows this phage to attack the bacterial K5 capsule (12, 14). We have demonstrated that it is possible for a phage to have both tail proteins, the Kl endosialdase as well as the K5 lyase. Such a phage, which we have designated phage ΦK1-5, has an expanded host range as it can infect both E. coli Kl and E. coli K5. We have demonstrated that this expanded host range capability is due to the capacity of this ΦK1-5 phage to display both tail proteins, a Kl endosialidase as well as a K5 lyase. We have demonstrated through sequence analysis of ΦK1-5 phage tail protein genes that they are arranged in a modular or cassette structure, indicating that the host range of phages can be broadened for other K antigens, and even other bacteria species by recombinational techniques. The demonstration that a phage can contain multiple tail proteins that expand its host range is envisioned as being useful in generating phage with broad-spectrum antibacterial properties for the therapy and prophylaxis of infectious diseases. Recently there has been a renewed interest in the use of phages to treat and prevent bacterial infections (for a review see Barrow and Soothill, 1997, Trends Microbiol. 5(7), 268- 271). ΦK1-5 is highly lytic, non-lysogenic, very stable, and kills bacteria rapidly, all features that make it a good candidate for phage therapy. The phage ΦK1-5 has an additional advantage because it recognizes and attaches to the same structure(s) that confer virulence to the bacteria. In addition, bacteria that become resistant to phage usually have lost the polysaccharide capsule and are no longer virulent. Given these findings, ΦK1-5 is envisioned as being used as a general platform phage for therapeutic and prophylatic applications in which host specificity will be altered by engineering the tail protein genes. The capacity to engineer the expression of tail proteins is also envisioned as providing for phage that can transfer genes to organisms that are not normally infected by phage. Such a goal is to be achieved by expressing a mammalian viral protein on the tail of the phage to enable such a phage to transfer its genetic material into a mammalian cell. Phage with this capability will be of use in gene therapy applications. Referring to Figure 1, ΦK1-5 is an isolated bacteriophage consisting of an icosohedral head with a small tuft of short tail fibers that is able to infect and replicate on either Kl or K5 strains of E. coli. It appears that its ability to replicate on these strains is due to the fact that it encodes two different hydrolytic tail fiber proteins. One is an endosialidase protein, almost identical to a similar protein from ΦK1Ε, that allows it to attach to and degrade the Kl polysaccharide capsule. The other is almost identical to a lyase protein that has been shown to allow ΦK5 to attach to and degrade the K5 polysaccharide capsule. This is the first example of a phage that has a dual host specificity based on having two different tail proteins. Referring to Figure 2, all three of these phages share sequence similarity upstream of the region encoding the tail proteins and all have an ΦSP6-like promoter that probably drives transcription of the tail gene(s). In ΦK1-5 and ΦK5, the first gene downstream of this promoter is the K5 lyase protein. ΦK1Ε does not encode this protein and instead has a 111 amino acid ORF (ORF L ) of unknown function. Immediately downstream of the K5 lyase proteins of ΦK1-5 and ΦK5, and downstream of ORF L in ΦKIΕ is an 85 base region of similarity between all three phages. This region contains two strong symmetrical elements that may be involved in transcription termination. Further downstream, phages ΦK1-5 and ΦKIΕ encode the endosialidase gene. ΦK5 does not encode this gene but instead encodes the 523 amino acid ORF P . ΦK1-5 is a bacteriophage that we isolated from sewage using a K5 strain of E. coli as a host. By analyzing the host range of ΦK1-5, we found that it can replicate on either Kl or K5 strains. DNA sequence analysis of the tail fiber genes revealed that it encodes both a K5 lyase protein similar to that of ΦK5 and an endosialidase protein similar to that of ΦKIΕ. The arrangement of these genes indicates that phage host range can be broadened or changed by the acquisition of new tail genes by recombination in nature or by technology in the laboratory. ΦK5 also is able to replicate on K95 strains of E. coli (28). Since ORF P is in a position analogous to that of the endosialidase of ΦK1-5, it is also envisioned as a tail protein responsible for growth on K95 strains. Another K antigen specific phage, ΦK20, is also able to lyse two different types of E. coli hosts, those that possess the K5 antigen and those that possess the K20 polysaccharide (26). We envision ΦK20 as carrying a K5 lyase protein similar to the ΦK5/ΦK1-5 protein along with a K20 specific hydrolytic tail protein. Phages have also been isolated that are specific to the capsular antigens K3, K7, K12, and K13 of E. coli. Presumably these phages have corresponding K specific hydrolytic tail proteins. We envision other phages having multiple specificities with other combinations of K antigens. The host range of a bacteriophage is expanded beyond E. coli by expressing the genes encoding multiple different host tail proteins, a constraint being an understanding of the mechanism by which the tail protein is attached to the capsid structure of a phage. The N-terminus of the T7 tail protein is thought to be involved in attachment (29). Neither the endosialidase nor the K5 lyase has this region, or any other region similar to any other tail protein (or with each other). Morphologically, ΦKIΕ, ΦK5 and ΦK1-5, are similar to Salmonella phage P22. The tail protein of P22 has been extensively studied and is also a hydrolytic protein involved in degradation of the Salmonella typhimurium O antigen. This protein is a homotrimer with six copies per phage (30). The gpl7 tail-fiber of T7 is also a trimer with 6 copies of the trimer per phage particle (33). The endosialidase of ΦKIΕ is also a trimer (20), but it has yet to be shown that there are 6 copies of the trimer per phage particle. Bacteriophage 63D is another newly characterized sialidase containing phage in which it has been shown by electron microscopy that the sialidase is present with 6 copies per particle (21). This phage is quite different morphologically from ΦKIΕ, ΦK5, and ΦK1-5 and has a long tail similar to that of bacteriophage lambda, with the sialidase located at the end of the tail. Six copies of a trimeric tail protein appear to be a general structural motif. Assuming that the endosialidase and K5 lyase are also arranged in six copies per virion, it is interesting to speculate how the two tail proteins are arranged on the head structure of ΦKIΕ. They may be arranged in an alternating fashion where there are three copies of each (Figure 3a). In the case of P22, there is evidence that only three copies of the tail are needed for infection (16) suggesting that this model is theoretically possible. The fact that there are no common sequence similarities between the two tail proteins argues against this model, since one might predict a common motif within the tail proteins that is required to attach to similar regions of the head structure. An alternative model is that there may be 6 copies of each tail protein, one attached to the other (Figure 3b). Since the N-terminus of the T7 tail protein is thought to be involved in attachment of the tail protein to the head structure, this region of the protein and similar regions of other tail proteins (or alternative regions of tail proteins that mediate attachment of one to the other) are envisioned as serving the attachment function, so an understanding of the mechanism no longer acts as a constraint. Our findings indicate that phages ΦK5, ΦKIE, and ΦK1-5 all share a region of sequence similarity upstream of the tail proteins. This region contains a Salmonella phage SP6 promoter. The DNA sequence surrounding the promoter described in Nam et al., Gene 1986, 46:57 matched the analogous sequence in ΦK1-5. Based on this information, we designed a primer from this region to sequence downstream of the analogous region in phage ΦSP6. DNA sequencing identified an open reading frame that has a high degree of amino acid similarity to phage P22 tail protein. ΦP22 is a well characterized Salmonella phage that has a similar morphology to ΦSP6, but has a very different life cycle. (ΦP22 is lysogenic like E. coli phage lambda, and ΦSP6 is lytic like T7 or the three K antigen phages). The P22 tail protein also has a polysaccharide degradation activity. Immediately downstream of the SP6 tail gene lies the 85 base pair intergenic region common to ΦK5, ΦKIE and ΦK1-5, and shortly after that the DNA molecule ends. Figure 4 compares the regions encoding the tail proteins in all four phage. The SP6 tail protein is in the analogous position as the lyase protein of ΦK1-5 and ΦK5 and ORF L of ΦKIE. ΦSP6 shares the cassette structure of the three K phages, indicating that all four are closely related and differ mainly in the tail proteins. We envision replacing the lyase protein of ΦK1-5 with the SP6 tail to create a phage that can attack Salmonella and Kl E. coli. It should be easy to construct by homologous recombination because of the common sequence upstream of the tail proteins and the common 85 base sequence between the two tail proteins. An alternative is to create a phage that can attack Salmonella, Kl E. coli and K5 E. coli by designing a construct to encode all three proteins. In the case of ΦK1-5, we have evidence that broad host range evolved by the acquisition of a second specific tail protein. Thus, under the theory of modular evolution, in which duplications and rearrangements of regions within tail fiber genes of different phages seem to mediate changes in host specificity, we envision increasing host range even further by designing the acquisition of a third specific tail protein, a fourth specific tail protein, and multiple specific tail proteins. Definitions The term "isolated" requires that a material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally occurring phage present in a natural system is not isolated, but the same phage, separated from some or all of the coexisting materials in the natural system, is isolated. The term "purified" does not require absolute purity; rather it is intended as a relative definition, with reference to the purity of the material in its natural state. Purification of natural material to at least one order of magmtude, preferably two or three magnitudes, and more preferably four or five orders of magnitude is expressly contemplated. The term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. Multiple Host Specificity Based On Multiple Different Host Tail Proteins Phage therapy capitalizes on the ability of phage to lyse bacteria. With the increasing incidence of antibiotic resistant bacteria, there is a need to counteract them. The present invention meets that need by overcoming the additional disadvantage frequently raised to the use of phage, which is their excessively narrow host range. A prototype bacteriophage has a head and a tail. The head is an icosahedron. The tail consists of a hollow core. The whole apparatus functions as a syringe for injection of phage DNA into the interior of a bacterial cell. The life cycle is that viral genes are expressed, virions are assembled, and cellular lysis releases infectious particles into the medium. In this way, the bacteriophage kill the host pathogen. One way of evading a host's antibody response is for a bacterium to coat itself with a capsule. A capsule is a network of polymers that is usually composed of polysaccharides, but may be composed of proteins or protein-carbohydrate mixtures, and that resembles host tissue polymers. In E. coli, over 70 different polysaccharide or protein K antigens are currently recognized by the World Health Organization. Bacteriophage carry a tail protein that attaches to a surface structure of a bacterium by which the viral genome enters the infected cell. Some bacteriophage possess a tail protein that contains capsule-degrading enzymatic activity. These enzymes facilitate penetration by bacteriophage of the bacterial cell capsule. In Kl specific bacteriophage, the tail protein is a neuranimidase. In K5 specific bacteriophage, the tail protein is a lyase. In other K specific bacteriophage, the tail protein is another hydrolytic protein. Phylogenetic classification indicates that gram-negative bacteria form one group of bacteria. Escherichia, Shigella, Enterobacter and Salmonella are genera of bacteria that are closely related to each other. Yersinia and Vibrio are the genera next most closely related to the E. coli group. Serratia and Klebsiella are the genera next most closely related to the E. coli group. Campylobacter is also the genera of Proteobacteria phylum. The genera Legionella, Pseudomonas, and Neisseria are more distantly related. Bordetellά's relationship is unknown. Helicobacter is the most distantly related genus in the E. coli group of gram-negative bacteria. The gram-positive bacteria form another group, with Listeria more closely related to the gram-positive cocci Staphylococcus and Streptococcus, Enterococcus and Clostridium, than to other gram-positive rods. Corynebacterium is most closely related to Mycobacterium. The spirochetes Treponema and Borrelia form a third phylogenetic group, while Chlamydia is related more distantly to this group. Despite the genetic diversity represented by pathogenic bacteria, similar strategies for overcoming host defenses have evolved in very different types of bacteria. We contemplate using our invention against but not limited to the following pathogenic bacteria presented in the table below. Where: "+, ATCC" indicates the presence of a corresponding bacteriophage(s) in the ATCC; "+, ref indicates that information on the excisting corresponding bacteriophage can be found in the following scientific literature: ref - Holzmayer TA, et al. 1988 Zentralbl Bakteriol Mikrobiol Hyg [A] 269(2): 147-55; Gol'tsmaier TA, et al. 1987 Zh Mikrobiol Epidemiol Immunobiol 5:9-13; ref b - Heintschel von Heinegg E, ey al. 1993 J Med Microbiol 38(4):245-9; ref - Ritchie AE, et al. 1978 Vet Rec 103(2):34- 5; ref - Eggers CH, et al. 2000 J Mol Microbiol Biotechnol2(4):365-73; ref - Hsia R, et al. 2000 Microbes Infect 2(7):761-72; Hsia RC, et al. 2000 Microbiology 146 ( Pt 7): 1651-60. In an embodiment of the present invention, a phage has a dual host specificity based on having two different host tail proteins. In another embodiment, a phage has a triple host specificity based on having three different host tail proteins. In a further embodiment, a phage has a quadruple host specificity based on having four different host tail proteins. And so forth, so that in an additional embodiment, a phage has a multiple host specificity based on having multiple different host tail proteins. In another embodiment of the present invention, a phage having a hydrolytic tail protein has a dual host specificity based on having two different hydrolytic tail proteins. In another embodiment, a phage having a hydrolytic tail protein has a triple host specificity based on having three different hydrolytic tail proteins. In a further embodiment, a phage having a hydrolytic tail protein has a quadruple host specificity based on having four different hydrolytic tail proteins. And so forth, so that in an additional embodiment, a phage having a hydrolytic tail protein has a multiple host specificity based on having multiple different hydrolytic tail proteins. In another embodiment of the present invention, a phage having a K specific hydrolytic tail protein has a dual host specificity based on having two different K specific hydrolytic tail proteins. In another embodiment, a phage having a K specific hydrolytic tail protein has a triple host specificity based on having three different K specific hydrolytic tail proteins. In a further embodiment, a phage having a K specific hydrolytic tail protein has a quadruple host specificity based on having four different K specific hydrolytic tail proteins. And so forth, so that in an additional embodiment, a phage having a K specific hydrolytic tail protein has a multiple host specificity based on having multiple different K specific hydrolytic tail proteins. A first example of a phage that has a dual host specificity is ΦK1-5. An example of a phage having a triple host specificity is ΦK1-5 having a third different tail protein. An example of a phage having a quadruple host specificity is ΦK1-5 having a third and fourth different tail protein. And so forth, so that an example of a phage having a multiple host specificity is ΦK1-5 having multiple different host tail proteins. A second example of a phage that has a dual host specificity is ΦKIE having a second different tail protein, like Kl-5. An example of a phage having a triple host specificity is ΦKIE having a second and third different tail protein. An example of a phage having a quadruple host specificity is ΦKIE having a second, third and fourth different tail protein. And so forth, so that an example of a phage having a multiple host specificity is ΦKIE having multiple different host tail proteins. A third example of a phage that has a dual host specificity is ΦK5 having a second different tail protein, like Kl-5. An example of a phage having a triple host specificity is ΦK5 having a second and third different tail protein. An example of a phage having a quadruple host specificity is ΦK5 having a second, third and fourth different tail protein. And so forth, so that an example of a phage having a multiple host specificity is ΦK5 having multiple different host tail proteins. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Escherichia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Shigella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Salmonella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Enterobacter and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Yersinia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Vibrio and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Legionella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Pseudomonas and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Neisseria and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Bordetella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Helicobacter and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Listeria and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, ' Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Staphylococcus and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Streptococcus and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Enterococcus and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Clostridium and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Corynebacterium and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Mycobacterium and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, ■ Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Treponema and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Borrelia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Campylobacter and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Chlamydia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Haemophilus and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Serratia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects Klebsiella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. Host Range Of Phage To Include Bacterial Cells Requiring Co-factors In another embodiment of the present invention, a phage that has a multiple host specificity based on having multiple different host tail proteins additionally has a gene encoding a co-factor that permits it to grow in other types of bacteria. Having the proper tail proteins is necessary for a phage to infect a strain of bacteria, as illustrated by the present experiments. For example, a phage having different host tail proteins is capable of infecting multiple hosts where the host expresses at least one of these host tail proteins. Nevertheless, additional factors may be necessary for a phage to infect other strains of bacteria. The present invention provides these phage where co- factors may also be needed to increase their host range. For example the E. coli phage lambda does not generally infect Salmonella. E. coli phage lambda requires a functional E. coli Nus A gene for lambda promoted transcription/anti-teπnination of DNA^ RNA to permit the virus to replicate and function. As the bacteria Salmonella does not have the E. coli Nus A gene, lambda cannot grow in Salmonella. When the E. coli Nus A gene is cloned into the lambda genome, this virus can then infect certain Salmonella stains. In a confirmatory experiment, the E. coli genome was cut into fragments with restriction enzymes and the fragments cloned into a lambda library. When these lambda phage were plated on Salmonella, only those containing E. coli Nus A gene grew. Thus, lambda carrying the E. coli Nus A gene provides one example of how the host range of a phage can be expanded. In another example of a phage that does not generally infect another type of bacteria, the gene that permits the virus to replicate and function in the bacteria may be known. If known, the gene can be cloned into the viral genome so that this virus can then infect other types of bacteria. If unknown, the gene can be identified, for example, by cutting the bacterial genome into fragments with restriction enzymes and then cloning the fragments into a library of that virus. When these phage are plated on the bacteria, only those containing the gene will grow. Thus, the gene that permits the virus to replicate and function in the bacteria can be identified. Once the gene is known, virus can be engineered to carry the gene. Thus, the host range of the phage can be expanded even when co-factors are necessary to grow in other types of bacteria. Host Range of Phage To include Mammalian Cells In another embodiment of the present invention, a phage has mammalian host specificity based on incorporating the gene for a cell surface-receptor ligand into the phage genome such that it is expressed on the tail of the phage, thus faciliating receptor mediated endocytosis. Poul et al, J Mol Biol 1999, 288:203 and Larocca et al., FASEB J 1999, 13:727 describe gene delivery to mammalian cells by bacteriophage expressing cell surface-receptor ligands as genetic fusions with phage coat proteins or presenting cell surface-receptor ligands on the coats of phage, with the goal being the development of gene therapy vectors. The present invention envisions substituting phage tail proteins. A cell surface-receptor ligand is genetically fused to a phage tail protein or otherwise presented on the tails of phage. Nucleotide sequences encoding ligand-phage fusions or cell surface-receptor ligands themselves may also be modified by insertion of mammalian reporter genes to test for binding, internalization, and expression. Ultimately, the mammalian reporter gene is replaced by a therapeutic nucleotide sequence. The therapeutic nucleotide sequence encodes a factor having a therapeutic effect. In alternative embodiments, a factor is a protein cytocide, an antisense, a ribozyme, a dominant negative mutant, or a therapeutic protein (e.g., a growth factor, a hormone, a cytokine, a receptor, or a ligand). An example of receptor-mediated gene delivery using bacteriophage vectors displaying ligands as genetic fusions with phage coat proteins or presenting cell surface-receptor ligands on the coats of phage is set forth in USP 6,054,312 to Larocca et al. Methods of Making In a different embodiment, the acquisition of new tail genes occurs by recombination in nature. In an alternative embodiment, the acquisition of new tail genes is generated by technology in the laboratory. Thus, the phage may be developed by selection or engineering. Phage that have multiple specificities may be selected by assays to determine the host range of phages, such as plaque assays. Alternatively, phage that have multiple specificities may be engineered by cloning the gene for a tail protein into a plasmid vector system and then incorporating this configuration into the phage of interest by an in vivo generalized recombination system in the host bacteria for the phage of interest; or by cloning the gene for a first tail protein into a plasmid vector system, and then cloning the gene for a second tail protein into this carrying vector by in-frame fusion at the 3'- or 5'- end of the gene for the first tail protein, and then incorporating this configuration into the phage of interest by an in vivo generalized recombination system in the host bacteria for the phage of interest; or by cloning the gene for a first tail protein into a plasmid vector system, and then cloning the gene for a second tail protein into this carrying vector by in-frame fusion at the 3'- or 5'- end of the gene for the first tail protein, and then cloning the gene for a third tail protein into this carrying vector by in-frame fusion at the 3'- or 5'- end of the genes for the first and second tail proteins, and so forth, and then incorporating this configuration into the phage of interest by an in vivo generalized recombination system in the host bacteria for the phage of interest. Methods of Using. Formulations, and Administration The present invention can be applied across the spectrum of bacterial diseases, by selecting or engineering phages, so that phages are developed that are specific for more than one bacterial strain of interest. In that way, a full array of polyvalent bacteriophages is developed for virtually all the bacterial pathogens for man, his pets, livestock and zoo animals (whether mammal, avian, or pisciculture). Phage therapy will then be available: 1) as an adjunct to or as a replacement for those antibiotics and/or chemotherapeutic drugs that are no longer functioning in a bacteriostatic or bactericidal manner due to the development of multi-drug resistance; 2) as a treatment for those patients who are allergic to the antibiotics and/or chemotherapeutic drugs that would otherwise be indicated; and 3) as a treatment that has fewer side effects than many of the antibiotics and/or chemotherapeutic drugs that would otherwise be indicated for a given infection. Another embodiment of the present invention is the development of methods to treat bacterial infections in animals through phage therapy with the polyvalent bacteriophages described above. Hundreds of bacteriophages and the bacterial species they infect are known in the art. The present invention can be utilized to develop polyvalent bacteriophages that can be used to treat any and all infections caused by their host bacteria. While it is contemplated that the present invention can be used to treat any bacterial infection in an animal and human, it is particularly contemplated that the methods described herein will be very useful as a therapy (adjunctive or stand-alone) in infections caused by drug-resistant bacteria. Experts report (See e.g. Gibbons, A., "Exploring New Strategies to Fight Drug-Resistant Microbes, Science, 21 Aug. 1993, pp. 1036-38) that at the present time, the drug-resistant bacterial species and strains listed below represent the greatest threat to mankind: 1. All of the clinically important members of the family Enterobacteriaceae, most notably but not limited to the following: a) All the clinically important strains of Escherichia, most notably E. coli. One among a number of candidate wild-type phages against these particular pathogens that could be used as a starting point for the genetic engineering of the present invention would be ΘK1-5 having ATCC Accession No. # PTA-3495. (Note: For purposes of brevity, in all the following examples of pathogens, the corresponding wild-type phage will be indicated by the following phraseology: "Example of corresponding phage: "•) b) All the clinically important strains of Klebsiella, most notably K. pneumoniae (Example of corresponding phage: ATCC phage #23356-Bl). c) All the clinically important strains of Shigella, most notably S. dysenteriae (Example of corresponding phage: ATCC phage #11456a-Bl). d) All the clinically important strains of Salmonella, including S. abortus-equi (Example of corresponding phage: ATCC phage #9842-Bl), S. typhi (Example of corresponding phage: ATCC phage #19937-B1) S. typhimurium (Example of corresponding phage: ATCC phage #19585-B1), S. newport (Example of corresponding phage: ATCC phage #27869-Bl), S. paratyphi-A (Example of corresponding phage: ATCC phage #12176-B1), S. paratyphi-B (Example of corresponding phage: ATCC phage #19940-B1), S. potsdam (Example of corresponding phage: ATCC phage #25957-B2), and S. pollurum (Example of corresponding phage: ATCC phage #19945- Bl). e) All the clinically important strains of Serratia, most notably S. marcescens (Example of corresponding phage: ATCC phage #14764-B1). f) All the clinically important strains of Yersinia, most notably Y. pestis (Example of corresponding phage: ATCC phage #11953-B1). g) All the clinically important strains of Enterobacter, most notably E. cloacae (Example of corresponding phage : ATCC phage #23355 -B 1 ) . 2. All the clinically important Enterococci, most notably E. faecalis (Example of corresponding phage: ATCC phage #19948-B1) and E. faecium (Example of corresponding phage: ATCC phage #19953-B1). 3. All the clinically important Haemophilus strains, most notably H. influenzae (a corresponding phage is not available from ATCC for this pathogen, but several can be obtained from WHO or other labs that make them available publicly). 4. All the clinically important Mycobacteria, most notably M. tuberculosis (Example of corresponding phage: ATCC phage #25618-B1), M. avium-intracellulare, M. bovis, and M. leprae. (Corresponding phages for these pathogens are available commercially from WHO, via The National Institute of Public Healthy & Environmental Protection, Bilthoven, The Netherlands). 5. Neisseria gonorrhoeae and N. meningitidis (Corresponding phage for both can be obtained publicly from WHO or other sources). 6. All the clinically important Pseudomonads, most notably P. aeuruginosa (Example of corresponding phage: ATCC phage #14203-B1). 7. All the clinically important Staphylococci, most notably S. aureus (Example of corresponding phage: ATCC phage #27690-Bl) and S. epidermidis (Corresponding phage are available publicly through the WHO, via the Colindale Institute in London). 8. All the clinically important Streptococci, most notably S. pneumoniae (Corresponding phage can be obtained publicly from WHO or other sources). 9. Vibrio cholera (Example of corresponding phage: ATCC phage #14100-B1). There are additional bacterial pathogens too numerous to mention that, while not currently in the state of antibiotic-resistance crisis, nevertheless make excellent candidates for treatment with polyvalent bacteriophages in accordance with the present invention. Thus, all bacterial infections caused by bacteria for which there is a corresponding phage can be treated using the present invention. Any phage strain capable of doing direct or indirect harm to a bacteria (or other pathogen) is contemplated as useful in the present invention. Thus, phages that are lytic, phages that are lysogenic but can later become lytic, and nonlytic phages that can deliver a product that will be harmful to the bacteria are all useful in the present invention. The animals to be treated by the methods of the present invention include but are not limited to man, his domestic pets, livestock, pisciculture, and the animals in zoos and aquatic parks. The polyvalent bacteriophages of the present invention can be used as a standalone therapy or as an adjunctive therapy for the treatment of bacterial infections. Numerous antimicrobial agents (including antibiotics and chemotherapeutic agents) are known in the art, which would be useful in combination with polyvalent bacteriophages for treating bacterial infections. Examples of suitable antimicrobial agents and the bacterial infections that can be treated with the specified antimicrobial agents are listed below. However, the present invention is not limited to the antimicrobial agents listed below as one skilled in the art could easily determine other antimicrobial agents useful in combination with polyvalent bacteriophages. Pathogen Antimicrobial or antimicrobial group E. coli Uncomplicated urinary tract trimethoprim-sulfamethoxazole (abbrev. infection TMO-SMO), or ampicillin; 1st generation cephalosporins, ciprofloxacin Systemic infection ampicillin, or a 3rd generation cephalosporin; aminoglycosides, aztreonam, or a penicillin + a pencillinase inhibitor Klebsiella pneumoniae 1st generation cephalosporins; 3rd gener. cephalosporins, cefotaxime, moxalactam, amikacin, chloramphenicol Shisella (various) ciprofloxacin; TMO-SMO, ampicillin, chloramphenicol Salmonella: s. typhi chloramphenicol; ampicillin or TMO-SMO Non-typhi species ampicillin; chloramphenicol, TMO-SMO, ciprofloxacin Yersinia pestis streptomycin; tetracycline, chloramphenicol Enterobacter cloacoe 3rd generation cephalosporins, gentamicin, or tobramycin; carbenicilhn, amikacin, ztreonam, imipenem Hemophilus influenzae: Meningitis chloramphenicol or 3rd generation cephalosporins; ampicillin Other H. infl. Infections ampicillin; TMO-SMO, cefaclor, cefuroxime, ciprofloxacin Mycobacterium tuberculosis andM. isoniazid (INH) + rifampin or rifabutin, the avium-intracellulare above given along with pyrazinamide +/or ethambutol Neisseria: N. meningitidis penicillin G; chloramphenicol, or a sulfonamide N. gonorrhoeae: Penicillin-sensitive penicillin G; spectinomycin, ceftriaxone Penicilin-resistant cefhϊaxone; spectinomycin, cefuroxime or cefoxitin, ciprofloxacin Pseudomonas aerueinosa tobramycin or gentamycin (+/- carbenicillin, aminoglycosides); amikacin, ceftazidime, aztreonam, imipenem Staph aureus non-penicillinase producing penicillin G; 1st generation cephalosporins, vancomycin, imipenem, erythromycin Penicillinase producing a penicillinase-resisting penicillin; 1st generation cephalosporins, vanco-mycin, imipenem, erythromycin Streptococcus pneumoniae penicillin G; 1st generation cephalosporins, erythromycin, chloramphenicol Vibrio cholera tetracycline; TMO-SMO In another embodiment of the present invention, the polyvalent bacteria of the invention are provided as compositions useful in the treatment and prevention of various bacterial infections, such as diarrhea, dysentery, hemolytic uremic syndrome, bladder infection, kidney infection, urinary tract infection, septicemia, pneumoma, and meningitis, and other various diseases, syndromes, and disorders. The polyvalent bacteriophage of the invention can be used for the treatment or prevention of Hemophilus influenza, Pseudomonas, Streptococcus pneumoniae, Streptococcus fasciae, Streptococcus group B, Listeria, Salmonella, E. coli, Campylobacter, and other bacteria, and any combination thereof. For example, if there is a bacterial infection of the upper respiratory tract, the infection can be prophylactically or therapeutically treated with a composition comprising at least one polyvalent bacteriophage specific for that bacteria, and a carrier for delivering the polyvalent bacteriophage to a mouth, throat, or nasal passage. If an individual has been exposed to someone with the upper respiratory disorder, the polyvalent bacteriophage will reside in the mucosal lining and prevent any colonization of the infecting bacteria. Two examples of bacteria which infect the upper respiratory system are Streptococcus pneumoniae and Hemophilus influenzae. In recent years, there has been an increase in the number of people, particularly children and the elderly, that are infected or are carriers of penicillin resistant Streptococcus pneumoniae and Hemophilus. While these bacteria are normally harmless residents of the host, they are opportunistic organisms that are able to cause infections when the resistance of the host has been compromised. By eliminating or reducing the number of these organisms in the upper respiratory tract, there will be a commensurate reduction in the number of infections by these bacteria. The Hemophilus bacteria is infected by bacteriophage HP1 (a member of the P2- like phage family with strong similarities to coliphages P2 and 186, and some similarity to the retronphage Ec67), which produces a lytic enzyme capable of lysing the bacteria. Streptococcus pneumoniae is infected with the Pal bacteriophage, which produces a lytic enzyme identified as an N-acetyl-muramoyl-L-alanine amidase. The pharmaceutical composition of the invention can contain either one polyvalent bacteriophage that recognizes these two bacteria, and may contain other polyvalent bacteriophage for other bacteria. The composition which may be used for the prophylactic and therapeutic treatment of a strep infection includes the polyvalent bacteriophage and a means of application, (such as a carrier system or an oral delivery mode), to the mucosal lining of the oral and nasal cavity, such that the polyvalent bacteriophage is put in the carrier system or oral delivery mode to reach the mucosal lining. Another infection which can be treated prophylactically is Streptococcus group A, which can produce what is commonly known as "strep" throat. Group A Streptococci are infected with a Cl bacteriophage, which produces a lysing enzyme specific for the lysing of Streptococcus group A. Another use of a polyvalent bacteriophage of the invention is for the treatment of bacterial infections of the digestive tract. The method for treating a bacterial infection of the digestive tract comprises treating the bacterial infection with composition comprising an effective amount of at least one polyvalent bacteriophage specific for the bacteria, and a carrier for delivering said polyvalent bacteriophage to the digestive tract. In a preferred embodiment of the invention, the bacterial infections being treated are being caused by gram negative bacteria selected from the group consisting of Listeria, Salmonella, E. coli, and Campylobacter. However, this method and composition will effectively treat other bacteria, when the appropriate polyvalent bacteriophage is used. Another composition and use of the polyvalent bacteriophage of the invention is for the therapeutic or prophylactic treatment of bacterial infections of burns and wounds of the skin. The composition comprises an effective amount of at least one polyvalent bacteriophage specific for the bacteria and a carrier for delivering at least one polyvalent bacteriophage to the wounded skin. The polyvalent bacteriophage may be applied to a bandage either directly or in one or another carrier. The bandages may be sold damp or dry, wherein the polyvalent bacteriophage is in a lyophilized form on the bandage. This method of application is most effective for the treatment of burns. In some embodiments of the invention, polyvalent bacteriophage for Pseudomonas, Staphylococcus, and Streptococcus, jointly or individually, may be incorporated into one or another carrier, or into a bandage to be used on burn patients. Yet another use of polyvalent bacteriophages is for the bacterial infections caused by Kl and/or K5 strains of E. coli. These bacteria are involved in a variety of infections, the most common are urinary tract infections (UTI). The polyvalent bacteriophage of the present invention would be applied directly to the site of infection, in the case of UTI this would mean to deliver the phage to the bladder through a catheter. In the case of septicemias caused by Kl E coli, the polyvalent phage of the present invention could be injected directly into the circulatory system or intraperitoneally. In case of meningitis caused by E. coli, the polyvalent phage of the present invention will be delivered to the cerebro-spinal fluid or directly applied to the brain or meninges. Yet another use of the polyvalent bacteriophages of the invention is for the prophylactic or therapeutic treatment of vaginal infections. This treatment comprises treating the vaginal infection with an effective amount of at least one polyvalent bacteriophage specific for that bacteria, wherein that polyvalent bacteriophage is incorporated in a carrier to be placed in a vagina. The preferred carrier is a tampon, or vaginal douche. A pad may also be used as a carrier, although it is not as effective. While any number of bacteria could be treated using this composition and method, it is believed that the most optimum use of this treatment composition and method would be for the treatment of an E. coli and Streptococcus B infection. Vaginal infections caused by Group B Streptococcus can cause neonatal meningitis resulting in brain damage and premature death. Polyvalent bacteriophage incorporated into tampons specific for group B Strep would eliminate the group B organisms without disturbing normal flora so that women would not be overcome by yeast infections post antibiotic therapy. The use of the polyvalent bacteriophage in the vagina would best provide a prophylactic effect, although therapeutic use would also be advisable. Another use of the invention is for the prophylactic and therapeutic treatment of eye infections. The method of treatment comprises administering eye drops which comprise an effective amount of at least one polyvalent bacteriophage specific for the bacteria and a carrier capable of being safely applied to an eye, with the carrier containing the polyvalent bacteriophage. In some embodiments of the invention, the bacteria being treated is Hemophilus or Staphylococcus. The eye drops are in the form of an isotonic solution. Polyvalent bacteriophage can also be used to fight dental caries. Specifically, a polyvalent bacteriophage specific for Streptococcus mutans may be incorporated in a toothpaste or oral wash. Similarly, this polyvalent bacteriophage may also be incorporated into a chewing gum or lozenge. Any other carrier can be used that allows for the exposure of the mouth, gums, and teeth to the polyvalent bacteriophage. The routes of administration include but are not limited to oral, aerosol, intranasal, intravenous, intramuscular, intraperitoneal, intrathecal, vaginal, rectal, topical, lumbar puncture, and direct application to the brain or meninges. Pharmaceutically acceptable excipients which can be used as a vehicle for the delivery of the phage will be apparent to those skilled in the art. For example, the free phage could be in lyophilized form and be dissolved just prior to administration by IN injection. The dosage of administration is contemplated to be in the range of about 10 6 to about 10 13 pfu/per kg/per day, and preferably about 10 12 pfu/per kg/per day. The phage are administered until successful elimination of the pathogenic bacteria is achieved. With respect to the aerosol administration to the lungs, the polyvalent bacteriophage is incorporated into an aerosol formulation specifically designed for administration to the lungs by inhalation. Many such aerosols are known in the art, and the present invention is not limited to any particular formulation. An example of such an aerosol is the Proventil™ inhaler manufactured by Schering-Plough, the propellant of which contains trichloromonofluoromethane, dichlorodifluoromethane and oleic acid. The concentrations of the propellant ingredients and emulsifiers are adjusted if necessary based on the phage being used in the treatment. The number of phage to be administered per aerosol treatment will be in the range of 10 6 to 10 13 pfu, and preferably 10 12 pfu. Isolation and Characterization of ΦK1-5 ΦK1-5 was isolated using E. coli ATCC 23506 (K5) as a host. Electron micrographs show that ΦK1-5 is morphologically similar to the Podoviridae family, which includes coliphages T7, T3, and Salmonella phages SP6 and P22. The phage particle consists of an icosohedral head of about 60 nm in diameter with a small tuft of short tail fibers (Figure 1). ΦK1-5 is highly lytic. When phage were added to a logarithmic culture of a susceptible host at an multiplicity of infection (moi) of 1:1, lysis occurs in 15-20 min. Burst size was determined by a one step growth curve and found to be to be about 110. ΦK1-5 plaques are clear and large, about 4.0-5.0 mm in diameter with a halo of about 12.0-15.0 mm in diameter on LB agar plates. The plaques reached a limit in size after 24 hours. In contrast, T7 plaques, can continue to grow for several days (38). DΝA was isolated from cesium chloride density gradient purified phage by phenol extraction. Digestion of the DΝA with several restriction enzymes indicated that it is double stranded, with an estimated size of 40 kb. Extended host range of ΦK1-5 The host range of ΦK1-5 was compared to that of ΦKIE (Kl antigen specific) and ΦK5 (K5 antigen specific). E. coli strains ATCC 23506 and ATCC 23508 possess the K5 polysaccharide capsule, and strains ATCC 23503 and ATCC 23511 possess the Kl capsule. Also tested was a set of K5 strains collected by Ian Roberts from the University of Manchester and a set of Kl isolates collected by Richard Silver from the University of Rochester (Table 1). ΦK1-5 is able to infect and grow on all of the Kl and K5 strains, ΦKIE only grows on the Kl strains and ΦK5 only grows on the K5 strains. ΦKIE, ΦK5, and ΦK1-5 were also tested for growth on the following ATCC strains: 23502 (K4), 23504 (K8), 23505 (K9), 23507 (K10), 23509 (Kll), 23510 (K14), 23515 (K17), 23516 (K20), 23517 (K13), 23518 (K18), 19110 (K7), 19138 (K2) and 31616 (K35). No phage growth by ΦK1-5, ΦKIE or ΦK5 was seen on any of these strains. TABLE 1. Host ranges of phages ΦKIE, ΦK5, ΦK1-5, ΦKl-5 (K1 - )? and K. -5^-? E. coli strain K antigen ΦK1-5 ΦKIE ΦK5 ΦKl-5^- ) ΦKl-5^ ATTCC 23503 Kl + + - - + ATCC 23511 Kl + + - - + RSI 64 Kl + + - - + RSI 66 Kl + + - - + RSI 67 Kl + + - - + RSI 68 Kl + + - - + RSI 76 Kl + + - - + RSI 79 Kl + + - - + RSI 80 Kl + + - - + RSI 88 Kl + + - - + RS203 Kl + + - - + RS215 Kl + + - - + RS218 Kl + + - - + RS228 Kl + + - - + ATCC 23506 K5 + - + + - ATCC 23508 K5 + - + + - 20026 K5 + - + + - 21195 K5 + - + + - 21386 K5 + - + + - 21786 K5 + - + + - 21795 K5 + - + + - 21831 K5 + - + + - 21832 K5 + - + + - 21834 K5 + - + + - 21835 K5 + - + + - a Plaque assays were done to determine host range of the phages against a collection of Kl and K5 strains of E. coli. ΦKIE only grows on Kl strains, ΦK5 only grows on ΦK5 strains and ΦK1-5 grows on are mutants of ΦK1-5 defective in growth on Kl and K5 stra ns, respect ve y. Because of the promoter sequence similarity between ΦK1-5 and SP6, we tested if ΦK1-5 could grow on Salmonella typhimurium strain LT2 (the host for SP6) and if SP6 could grow on any of the E. coli isolates sensitive to ΦK1-5. SP6 did not grow on any of the E. coli strains, and likewise ΦK1-5 did not grow on Salmonella typhymurium. ΦK1-5 encodes two tail genes ΦKIE and ΦK5 share a region of sequence similarity upstream of the tail proteins (including the SP6-like promoter, 3). Since ΦK1-5 had structural, biological and host similarities to these two phages, we speculated that all three may be closely related to and share this upstream sequence similarity. We designed a primer based on the sequence of this region in ΦKIE and ΦK5 to determine the sequence downstream of the promoter. When ΦK1-5 DNA was used as a template, the primer did hybridize, and we were able to generate sequence. We continued sequencing downstream by primer walking. The sequence immediately downstream of the promoter was very similar to ΦK5, and encoded an open reading frame with a high degree of sequence similarity (>92% amino acid identity) to that of ΦK5 tail protein. Continued sequencing downstream revealed a second open reading frame that is nearly identical (>97% amino acid identity) to the endosialidase protein of ΦKIE. An intergenic region of 85 base pairs lies between the termination codon of the lyase gene and the start codon of the endosialidase gene. This region is also present in ΦK5, immediately following the K5 lyase gene, and also in ΦKIE, immediately upstream of the endosialidase gene and immediately downstream of a 111 amino acid open reading frame (ORF L , 6). No recognizable promoter was found in this region, but there are two strong regions of symmetry, which may act as a Rho-independent transcriptional terminator. Sequence was determined 598 base pairs downstream of the termination codon of the endosialidase gene, at which point the end of the DNA molecule was reached. No open reading frames were found in this area. The sequence 500 base pairs upstream of the K5 lyase gene in ΦK1-5 was also determined. Like in the other phages, an SP6-like promoter is present and is probably required for transcription of the tail genes. The upstream sequence shares a high degree (>90%) of identity to that of the analogous region in ΦK5 and ΦKIE. We also sequenced downstream of the endosialidase gene of ΦKIE; 718 base pairs downstream from the endosialidase termination codon we reached the end of the DNA molecule. There is little sequence similarity between this region and the analogous region in ΦK1 -5. Each ΦK1-5 virion contains both tail proteins We addressed the question of whether ΦK1-5 particles contain both tail fiber proteins, or if two populations of particles (one containing the K5 lyase and the other containing the endosialidase) were produced after infection. We made a phage preparation using ATCC 23506 (K5) as a host and determined its titer on ATCC 23506 (K5) and ATCC 23503 (Kl) (Table 2). A sample of the phage was then incubated with ATCC 23506 for 5 min, which is long enough for phage to attach and possibly inject the DNA but not long enough for production of new phage particles. The MOI was 1/100 phage particle/bacteria. The mixture was then rapidly filtered. Phage particles that had attached to the cells would be eliminated from the filtrate. The filtrate was then titered on both the Kl and K5 strains. If the phage preparation was initially a mixture of two populations, then only those displaying the K5 lyase would attach and be eliminated. The remaining phage would be mainly those that contained the Kl specific endosialidase, and therefore the titer would be higher on the Kl E. coli strains than on the K5 strain. On the other hand, if each of the phage particles contained both tail proteins, titers of the phage remaining in the filtrate would be the same on the two strains, i.e., levels of the K5 lyase containing phages would not be selectively reduced. We found the latter to be the case and concluded that each virion has both the Kl endosialidase and the K5 lyase. Similar results were seen in the converse experiment in which the 5-min incubation was performed using the Kl E. coli strain (Table 2). As controls we performed the experiments with both ΦKIE and ΦK5, using both strains for the incubation. ΦKIE titers were reduced 99% by pre-incubation with the Kl strain but not with the K5 strain, and ΦK5 titers were similarly reduced after pre-incubation with the K5 strain but not with the Kl strain. TABLE 2. Preincubation experiments to show that all ΦK1-5 particles contain both tail proteins a Phage Titer ΦK1-5 Preincubated with 23506 5.2 x 10 8 Titered on 23506 after preincubation 3.1 x 10 6 Titered on 23503 after preincubation 3.7 x 10 6 Preincubated with 23503 5.2 x 10 8 Titered on 23506 after preincubation 6.8 x 10 6 Titered on 23503 after preincubation 6.4 x 10 6 ΦK5 Preincubated with 23506 4.0 x 10 8 Titered on 23506 after preincubation 8.5 x 10 5 Preincubated with 23503 4.0 x 10 8 Titered on 23506 after preincubation 3.3 x 10 8 ΦKIE Preincubated with 23506 7.7 x 10 8 Titered on 23503 after preincubation 6.8 x 10 8 Preincubation with 23503 7.7 x 10 8 Titered on 23503 after preincubation 3.0 x 10 6 'Preincubation of ΦK1-5 with either ATCC 23503 (Kl) or ATCC 23506 (K5) for 5 min results in roughly 100-fold loss of phage particles when titered on either strain. If the phage preparation consisted of two populations that each contained just one tail protein, then titers after the incubation would be reduced only on the strain that was used in the preincubation. ΦK5 titers are reduced by preincubation with a permissive host (23506) but not with a nonpermissive host (23503). ΦKIE titers are also reduced only by preincubation on a permissive host (23503) and not a nonpermissive host (23506). ΦK1-5 mutants defective in growth on either Kl or K5 E. coli A mixed lawn of Kl and K5 strains of E. coli was used to screen for ΦK1-5 mutants defective in growth on one or the other host strains. ΦK1-5 forms clear plaques on a mixed lawn of Kl and K5 E. coli; mutants in either tail would result in turbid plaques due to growth of the non-permissive host. Phage were treated with the mutagen hydroxylamine and plated on a double lawn. Turbid plaques were identified, picked, and purified by multiple plaque isolations on the double lawn. These were then screened by separately testing for growth on each strain. Of eight isolates purified, three were unable to plaque on the K5 strain but could plaque on the Kl strain. One of these, ΦK1- 5^ 5 - ) , was screened for growth against the entire host collection and found to be unable to replicate on any of the K5 strains but was able to grow on all of the Kl strains (Table 1). Five of the isolates could still replicate on both Kl and K5 strains but gave a turbid plaque morphology on the on the K5 strains. None of the mutants isolated in this way were defective in growth on Kl strains, so we devised a selection/amplification scheme to enrich for those that can replicate on K5 but not Kl hosts. Mutagenized phage were amplified on a K5 strain, filtered to remove bacterial debris, then used to infect a logarithmically growing Kl strain for 5 minutes. This mixture was rapidly filtered before phage burst could occur. Phage able to grow on Kl strain would attach to the cells and be eliminated from the filtrate. The sample was then re-amplified on the K5 strain and the cycle was repeated eight times. This strongly selects for phage that can replicate on K5 hosts but not Kl hosts. Titers of the filtrate were 200 fold higher on the K5 strain than on the Kl strain. Several were picked and purified by multiple rounds of single plaque isolation. One isolate, ΦK1- 5 ( κι was further characterized and found to be unable to grow on any of the Kl strains (Table 1). DNA sequence of a putative ΦK5 tail gene Clarke et. al. described a partial sequence of an open reading frame (ORFp) in ΦK5 immediately downstream of the 85 base region common to the three phages (6). We continued sequencing downstream and found the complete open reading frame is 523 amino acids. A BLAST search revealed a small region of sequence similarity with the N-acetylglucosamine-permease IIABC component near the Ν-terminus. It has no significant sequence similarity with any other entry in the database or any of the tail proteins described here. Sequence was determined an additional 163 bases downstream, at which point the end of the DΝA molecule was reached. Figure 2 compares the regions encoding tail proteins in all three phages. ΦK1-5 has a K5 lyase protein in the same position as that of ΦK5. ΦKIE has a 111 amino acid open reading frame (ORF L ) of unknown function in this position. Immediately downstream all three phages have an intergenic region of 85 bases that has two dyad axis of symmetry. Immediately downstream of this region ΦK1-5 encodes its endosialidase protein, which is in the analogous position as the ΦKIE endosialidase. ΦK5 encodes a 523 amino acid open reading frame (ORF P ) in this position. The three phages share sequence similarity upstream of the tail genes. No sequence similarity was noted downstream, and in all three phages the DNA molecule ends downstream. EXAMPLE 1 Isolation of Kl-5 ΦK1-5 was isolated from raw sewage using the plaque technique. Briefly, a 1L sample of sewage was centrifuged at 6000 rpm in a GSA rotor to remove solid matter and was then passed through a 0.45 micron nitrocellulose filter (Nalgene). 100 μl of filtrate was added to 200 μl of an overnight culture of E. coli ATCC 23506 (K5) grown in LB media. 3 ml of melted tempered top agar (5 g/L agar in LB) was added and the mix was plated onto an LB agar plate and incubated at 37°C overnight. The following day plaques were picked and re-plaqued 3 times to insure pure culture. Final plaque isolates were stored as an agar plug from a Pasteur pipette deposited in 1 ml of SM buffer (10 mM MgSO 4 , 100 mM NaCl, 0.01% gelatin, 50 mM Tris pH 7.5). Host range was initially screened by spotting 10 μl of SM buffer containing a plaque plug onto a lawn of an appropriate strain. Host range of interesting phage isolates was further confirmed by the plaque assay. All phage titrations were done by the plaque assay technique. Large Scale Purification Phages were prepared by the cesium chloride density gradient method. 1 L of an appropriate host was grown up to and OD 600 of between 0.4 and 0.6 at 37°C with 200 rpm shaking in LB broth. Phage were added at a moi of 1 phage/100 bacteria, and the culture was allowed to incubate until the OD reached a minimum for 30 min. 10 ml of chloroform was added and allowed to shake for 10 min and was then centrifuged for 20 min at 6000 rpm in GSA rotor to remove cellular debris. The supernatant was collected and 1/10th volume of 5M NaCl and 1/10th w/v of polyethylene glycol was added to precipitate the phage, this was held at 4°C overnight. The phage were then pelleted by centrifugation at 6000 rpm in a GSA rotor at 4°C. The pellet was resuspended in phosphate buffered saline and CsCl was added to a density of 1.5 g/ml. The sample was spun in Ti80 (Beckman) rotor at 34,000 rpm overnight. The phage band was extracted with a syringe and was dialyzed against phosphate buffered saline (pH 7.4). DNA Isolation and Sequencing DNA was isolated from CsCl purified phage by phenol/chloroform extraction. The phage DNA was used directly as a template for DNA sequencing which was carried out by Commonwealth Biotechnologies in Richmond, NA . Both strands were sequenced (of the tail gene region of ΘK1-5). DΝA database searches were done by BLAST (1), and sequence alignments were performed with the Wisconsin Package (9). Mutagenesis Cesium purified phage were mutagenized with UN light using a model TM 36 chromatovue transilluminator (UVP, Inc.). Phage were typically exposed for 10-20 sec, which reduced viability by 1000 fold. The mutagenized phage were then amplified on ATCC 23503 or ATCC 23506 and subjected to selection and amplification as described above. Phage were also mutagenized by incubation with 400 mM hydroxylamine until the phage titer was reduced by 100 fold. They were then plated on a double lawn of ATCC 23503 and ATCC 23506. Turbid plaques were picked, replaqued for isolation, and tested for growth against a collection of Kl and K5 E. coli strains. REFERENCES 1. Altschul, S. F., W., Gish, W., Miller, E. W., Myers, D. J., and Lipman.1990. Basic local alignment search tool. J. Mol. Biol. 215(3): 403-410. 2. Botstein, D. 1980. A theory of modular evolution for bacteriophages. Ann. NY Acad. Sci. 354: 484-490. 3. Brown, J. E., J. F. Klement, and W. T. McAllister. 1986. Sequences of three promoters for the bacteriophage SP6 RNA polymerase. Nucleic Acids Res. (14)8: 3521-3526. 4. Campbell, A., and D. Botstein. 1983. Evolution of the lambdoid phages. In Lambda II. Cold Spring Harbor Laboratory. 365-380. 5. Chandry, P. S., S. C. Moore, J. D. Boyce, B. E. Davidson, and A. J. Hillier. 1997. Analysis of the DNA sequence, gene expression, origin of replication, and modular structure of the Lactococcus lactis lytic bacteriophage ski. Mol. Microbiol. 26(1): 49-64. 6. Clarke, B. R., F. Esumah, and I. S. Roberts. 2000. Cloning, expression, and purification of the K5 capsular polsaccharide lyase (KflA) from coliphage K5A: evidence for two distinct K5 lyase enzymens. J. Bacteriol. 182(13): 3761-3766. 7. Crawford, J.T. and E.B. Goldberg. 1980. The function of the tail fibers in triggering baseplate expansion of bacteriophage T4. J. Mol. Biol. 139: 679-690. 8. Desiere, F., S. Lucchini, and H. Brussow. 1998. Evolution of Streptococcus thermophilus bacteriophage genomes by modular exchanges followed by point mutations and small deletions and insertions. Virology. 241(2): 345-356. 9. Devereux, J., P. Haeberli, and O. Smithies. 1984. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 12(1): 387-395. 10. Gross, R. J., T. Cheasty, and B. Rowe. 1977. Isolation of bacteriophages specific for the Kl polysaccharide antigen of E. coli. J. Clin. Microbiol. 6(6): 548-550. 11. Gupta, D. S., B. Jann, G. Schmidt, J. R. Golecki, I. ørskov, F. ørskov, and K. Jann. 1982. Coliphage K5, specific for E. coli exhibiting the capsular K5 antigen. FEMS Microbiol. Lett. 14: 75-78. 12. Gupta, D. S., B. Jann, and K. Jann. 1983. Enzymatic degradation of the capsular K5-antigen of E. coli by coliphage K5. FEMS Microbiol. Lett. 16: 13- 17. 13. Haggaard-Ljungquist, E., C. Hailing, and R. Calendar. 1992. DNA sequences of the tail fiber genes of bacteriophage P2: evidence for horizontal transfer of the tail fiber genes among unrelated bacteriophages. J. Bacteriol. 174(5): 1462-1477. 14. Hanfling, P., A. S. Shashkov, B. Jann, and K. Jann. 1996. Analysis of the enzymatic cleavage (beta elimination) of the capsular K5 polysaccharide of E. coli by the K5-specific coliphage: a reexamination. J. Bacteriol. 178(15): 4747- 4750. 15. Hendrix, R. W., M. C. M. Smith, R. N. Burns, M. E. Ford, and G. F. Hatfull. 1999. Evolutionary relationships among diverse bacteriophages and prophages: All the world's a phage. Proc. Natl. Acad. Sci., U.S.A. 96: 2192- 2197. 16. Israel, V. 1978. A model for the adsorption of phage P22 to Salmonella typhimurium. J. Gen. Virol. 40: 669-673. 17. Jann, K., and B. Jann. 1987 Polysacharide antigens of E. coli. Rev. Infect. Dis. 9(5): S517-S526. 18. Jeng S.T., S.H. Lay, and H.M. Lai. 1997. Transcription termination by bacteriophage T3 and SP6 RNA polymerases at Rho-independent terminators. Can J. Microbiol. 43(12): 1147-1156. 19. Juhala R. J., M. E. Ford, R. L. Duda, A.Youlton, G. F. Hatfull, and R. W. Hendrix. 2000. Genomic sequences of bacteriophages HK97 and HK022: Pervasive genetic mosaicism in the lambdoid bacteriophages. J. Mol. Biol. 299(1): 27-51. 20. Long, G. S., J. M. Bryant, P. W. Taylor, and J. P. Luzio. 1995. Complete nucleotide sequence of the gene encoding bacteriophage E endosialidase: implications for K1E endosialidase structure and function. Biochem. J. 309: 543-550. 21. Machida, Y., K. Miyake, K. Hattori, S. Yamamoto, M. Kawase, and S. Iijima. 2000. Structure and funtcion of a novel coliphage-associated sialidase. FEMS Microbiol. Lett. 182(2): 333-337. 22. Monod, C, M. Repoila, F. Kutateladze, F. Tetart, and H. M. Krisch. 1997. The genome of the Pseudo T-even bacteriophages, a diverse group that resembles T4. J. Mol. Biol. 267: 237-249. 23. Montag, D., H. Schwarz, and U. Henning. 1989. A component of the side tail fiber of Escherichia coli bacteriophage λ can functionally replace the receptor- recognizing part of a long tail fiber protein of unrelated bacteriophage T4. J. Bacteriol. 171(8): 4378-4384. 24. Montag, D., S. Hashemolhosseini, and U. Henning. 1990. Receptor recognizing proteins of T-even type bacteriophages. The receptor recognizing area of proteins 37 of phages T4 and Tula and Tulb. 25. Neve, H., K. I. Zenz, F. Desiere, A. Koch, K. J. Heller and H. Brussow. 1998. Comparison of the lysogeny modules from the temperate Streptococcus thermophilus bacteriophages TP-J34 and Sfi21: implications for the modular theory of phage evolution. Virology, 241(1): 61-72 26. Nimmich, W., G. Schmidt, and U. Krallmann-Wenzel. 1991. Two different E.coli capsular polysaccharide depolymerases each associated with one of the coliphage ΦK5 and ΦK20. FEMS Microbiol. Lett. 82: 137-142. 27. Nimmich, W., U. Krallman-Wenzel, B. Muller, and G. Schmidt. 1992. Isolation and characterization of bacteriophages specific for capsular antigens K3, K7, K12, and K13 of E. coli. h t. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 276(2): 213-220. 28. Nimmich, W. 1994. Detection of E. coli K95 strains by bacteriophages. J. Clin. Microbiol. 32(11): 2843-2845. 29. Fetter, J.G., and E. R. Vimr. 1993. Complete nucleotide sequence of the bacteriophage K1F tail gene encoding Endo-N-Acylneuraminidase (Endo-N) and comparison to an endo-N homolog in bacteriophage PK1E. J. Bacteriol. 175(14): 4354-4363. 30. Seckler, R. 1998. Folding and function of repetitive structure in the homotrimeric phage P22 tailspike protien. J. Struct. Biol. 122: 216-222. 31. Schicklmaier, P., and H. Schmeiger. 1997. Sequence comparison of the genes for immunity, DNA replication, and cell lysis of the P22-related Salmonella phages ES18 and L. Gene. 195: 93-100. 32. Silver, R. P., and E. R. Vimr. 1990. Polysialic acid capsule of E. coli Kl. in The Bacteria, vol. 11. Molecular basis of bacterial pathogenesis. pp 39-60. Academic Press, Inc., New York. 33. Steven, A.C., B. L. Trus, J. V. Maizel, M. Unser, D. A. D. Parry, J. S. Wall, J. F. Hainfϊeld, and W. F. Studier. 1988. Molecular substructure of a viral receptor-recognition protein. J. Mol. Biol. 200(2): 351-365. 34. Szybalski, W., and E. H. Szybalski. 1974. Visualization of the evolution of viral genomes. In Viruses, evolution and cancer, pp. 563-582. Academic Press, New York. 35. Tetart, F., F. Repoila, C. Monod, and H.M. Krisch. 1996. Bacteriophage T4 host range is expanded by duplications of a small domain of the tail fiber adhesion. J. Mol. Biol. 258(5): 726-731. 36. Tetart, F., C. Desplats, and H.M Krisch. 1998 Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesion specificity. J. Mol. Biol. 282(3): 543-556. 37. Tomlinson, S., and P. W. Taylor. 1985. Neuraminidase asssociated with coliphage E that specifically depolymerizes the E. coli Kl capsular polysaccharide. J. Virol. 55(2): 374-378. 38. Yin, J. 1993. Evolution of bacteriophage T7 in a growing plaque. J. Bacteriol. 175(5): 1272. While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All figures, tables, and appendices, as well as patents, applications, and publications, referred to above, are hereby incorporated by reference.

Claims: WHAT IS CLAIMED IS: 1. A pharmaceutical composition comprising a phage having multiple host specificity based on having multiple different host tail proteins and a pharmaceutically acceptable excipient. 2. A pharmaceutical composition according to claim 1, said phage having multiple different hydrolytic tail proteins. 3. A pharmaceutical composition according to claim 1, said phage having multiple different K specific hydrolytic tail proteins. 4. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of ΦK1-5 on deposit as ATCC Accession No. PTA-3495 irrespective of the tail gene region. 5. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of ΦK1-5 on deposit as ATCC Accession No. PTA-3495 including the tail gene region. 6. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of ΦKIE. 7. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of ΦK5. 8. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of ΦK20. 9. A pharmaceutical composition according to claim 1, wherein said phage infects Escherichia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 10. A pharmaceutical composition according to claim 1, wherein said phage infects Shigella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 11. A pharmaceutical composition according to claim 1, wherein said phage infects Salmonella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 12. A pharmaceutical composition according to claim 1, wherein said phage infects Enterobacter and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 13. A pharmaceutical composition according to claim 1, wherein said phage infects Yersinia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 14. A pharmaceutical composition according to claim 1, wherein said phage infects Vibrio and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 15. A pharmaceutical composition according to claim 1, wherein said phage infects Legionella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 16. A pharmaceutical composition according to claim 1, wherein said phage infects Pseudomonas and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 17. A pharmaceutical composition according to claim 1, wherein said phage infects Neisseria and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 18. A pharmaceutical composition according to claim 1, wherein said phage infects Bordetella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 19. A pharmaceutical composition according to claim 1, wherein said phage infects Helicobacter and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 20. A pharmaceutical composition according to claim 1, wherein said phage infects Listeria and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 21. A pharmaceutical composition according to claim 1, wherein said phage infects Staphylococcus and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 22. A pharmaceutical composition according to claim 1, wherein said phage infects Streptococcus and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 23. A pharmaceutical composition according to claim 1, wherein said phage infects Enterococcus and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 24. A pharmaceutical composition according to claim 1, wherein said phage infects Clostridium and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 25. A pharmaceutical composition according to claim 1, wherein said phage infects Corynebacterium and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 26. A pharmaceutical composition according to claim 1, wherein said phage infects Mycobacterium and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 27. A pharmaceutical composition according to claim 1, wherein said phage infects Treponema and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 28. A pharmaceutical composition according to claim 1, wherein said phage infects Borrelia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 29. A pharmaceutical composition according to claim 1, wherein said phage infects Campylobacter and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 30. A pharmaceutical composition according to claim 1, wherein said phage infects Chlamydia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 31. A pharmaceutical composition according to claim 1, wherein said phage infects Haemophilus and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 32. A pharmaceutical composition according to claim 1, wherein said phage infects Serratia and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 33. A pharmaceutical composition according to claim 1, wherein said phage infects Klebsiella and additionally infects a bacterium selected from the group consisting of Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella. 34. A pharmaceutical composition according to claim 1, said phage further having a gene encoding a factor that permits said phage to replicate and function in another type of bacteria generally not infected by said phage. 35. A pharmaceutical composition comprising a phage having mammalian host specificity by presenting on the tail of said phage a mammalian cell surface-receptor ligand, wherein the phage genome encodes a therapeutic gene product. 36. A pharmaceutical composition according to the preceding claim, wherein said therapeutic gene product is a protein cytocide, an antisense, a ribozyme, a dominant negative mutant, or a therapeutic protein. 37. A method of making a pharmaceutical composition comprising: (a) isolating a phage according to claim 1 wherein the acquisition of new tail genes occurs by recombination in nature; and (b) combining said phage with a pharmaceutically acceptable excipient. 38. A method of making a pharmaceutical composition comprising: (a) generating a phage according to claim 1 wherein the acquisition of new tail genes is generated by technology in the laboratory; and (b) combining said phage with a pharmaceutically acceptable excipient. 39. A method of preventing or treating bacterial infection comprising administering the pharmaceutical composition of any of claims 1-34 to an individual in need thereof to prevent or treat bacterial infection. 40. Use of the pharmaceutical composition of any of claims 1-34 for the preparation of a medicament for prevention or treatment of bacterial infection.

Inventors: ADHYA SANKAR, MERRIL CARL R, SCHOLL DEAL, ADHYA, SANKAR, MERRIL, CARL, R., SCHOLL, DEAL
Applicants: DASSLER KG ADI, MERRIL CARL R, SCHOLL DEAL, US HEALTH, ADHYA, SANKAR, MERRIL, CARL, R., SCHOLL, DEAL, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Application year: 2001
Main classification: A61K35
IPC codes: A61K35, A61P31, C12N7